Medical Research · Supplementary · from Medical Research
Case 1: Interpreting a Randomized Controlled Trial
Patient Presentation
Demographics: 62-year-old female retired nurse
Chief Complaint: "I read about a new blood pressure medication in a study and I want to know if I should switch."
History of Present Illness: A 62-year-old woman with a 12-year history of essential hypertension presents to her primary care physician requesting a medication change. She brings a printed copy of a recently published randomized controlled trial (RCT) from a major medical journal. The study compared a novel angiotensin receptor-neprilysin inhibitor (ARNI) to standard ACE inhibitor therapy for primary hypertension, concluding that the ARNI reduced cardiovascular events by 18% (HR 0.82, 95% CI 0.71-0.95, p=0.008).
The patient's blood pressure has been well-controlled on her current regimen of amlodipine 5 mg and lisinopril 20 mg daily, with clinic readings averaging 128/78 mmHg. She has no history of heart failure, which is the only current FDA-approved indication for the ARNI medication. She is concerned because her father died of a myocardial infarction at age 70.
The physician reviews the study with the patient and identifies several methodological issues: the trial was industry-funded, the primary endpoint was a composite of MI, stroke, cardiovascular death, and heart failure hospitalization (with heart failure hospitalization driving most of the benefit), the study population had a mean age of 71 with 68% having pre-existing cardiovascular disease, and 23% of participants in the ARNI arm discontinued the medication due to symptomatic hypotension.
Past Medical History:
- Essential hypertension (12 years)
- Hyperlipidemia
- Osteoporosis
- No history of heart failure, MI, or stroke
Medications:
- Amlodipine 5 mg daily
- Lisinopril 20 mg daily
- Atorvastatin 20 mg daily
- Calcium/Vitamin D supplement
- Alendronate 70 mg weekly
Social History:
- Retired nurse, health-literate
- Non-smoker, minimal alcohol
- Walks 30 minutes daily
- Married, supportive home environment
Family History:
- Father: MI at age 70 (fatal)
- Mother: hypertension, alive at 84
- Sister: type 2 diabetes
Physical Examination
- Vital Signs: BP 126/76 mmHg, HR 68 bpm, RR 14/min, Temp 36.7°C, SpO2 99% on room air
- General: Well-appearing, healthy female in no distress
- Cardiovascular: Regular rate and rhythm, no murmurs, no S3 or S4, JVP normal
- Lungs: Clear bilaterally
- Extremities: No edema, pulses intact
Workup and Results
Laboratory Studies:
| Test | Result | Reference Range |
|---|---|---|
| BMP | Normal | - |
| Creatinine | 0.8 mg/dL | 0.6-1.2 mg/dL |
| Potassium | 4.2 mEq/L | 3.5-5.0 mEq/L |
| LDL cholesterol | 92 mg/dL | <100 mg/dL |
| HbA1c | 5.6% | <5.7% |
| BNP | 22 pg/mL | <100 pg/mL |
| Urine albumin/creatinine | 12 mg/g | <30 mg/g |
Critical Appraisal of the Published RCT:
| Appraisal Domain | Finding | Concern Level |
|---|---|---|
| Randomization | Computer-generated, allocation concealed | Low |
| Blinding | Double-blind, matching placebo | Low |
| Sample size | N=8,400 (powered for composite endpoint) | Low |
| Funding source | Pharmaceutical manufacturer of ARNI | Moderate |
| Primary endpoint | Composite (MI, stroke, CV death, HF hospitalization) | Moderate |
| Component analysis | HF hospitalization drove 72% of composite benefit | High |
| Study population | Mean age 71, 68% with pre-existing CVD | High (external validity) |
| Discontinuation rate | 23% in ARNI arm (hypotension) vs. 9% control | High |
| Absolute risk reduction | 2.3% over 4.2 years | Moderate |
| NNT | 44 over 4.2 years | Moderate |
Clinical Image
Diagram illustrating key elements of critical appraisal for randomized controlled trials, including assessment of internal validity, external validity, and clinical significance versus statistical significance. Source: Educational illustration.
Diagnosis
Well-Controlled Hypertension on Current Therapy; Published RCT Not Applicable to Patient's Clinical Profile
Key Diagnostic Criteria:
- Patient's BP well-controlled at 126/76 mmHg on current regimen
- Study population differs significantly from patient (older, pre-existing CVD)
- Composite endpoint driven by heart failure hospitalization; patient has no heart failure
- High discontinuation rate (23%) suggesting poor tolerability
- Industry-funded trial with potential bias in endpoint selection
Treatment Plan
- Continue current antihypertensive regimen (amlodipine 5 mg + lisinopril 20 mg)
- No medication change warranted based on this trial's applicability to her clinical profile
- Explain concepts of external validity, composite endpoints, and absolute vs. relative risk reduction
- Discuss that a 18% relative risk reduction translates to a 2.3% absolute risk reduction (NNT 44)
- Reinforce importance of modifiable risk factor management (exercise, diet, lipid control)
- Monitor for future studies specifically enrolling primary prevention hypertension populations
- Annual cardiovascular risk reassessment
Key Learning Points
- Relative risk reduction (18%) often appears more impressive than absolute risk reduction (2.3%); always calculate both when evaluating trial results
- Composite endpoints can mask which components drive the overall result; component analysis is essential
- External validity (generalizability) must be assessed: applying trial results from high-risk secondary prevention populations to low-risk primary prevention patients may be inappropriate
- Industry funding does not invalidate a trial but warrants scrutiny of endpoint selection, comparator choice, and reporting of adverse effects
- Number needed to treat (NNT) provides a clinically intuitive measure of treatment benefit that aids shared decision-making